Academic scientist receives $125,000 from ADDF/LBDA program to review LBD The Alzheimer’s Drug Discovery Basis and the Lewy Body Dementia Association announced today the recipient of their first partnership research award through the Lewy Body Dementia Biomarker Study Program. The purpose of the scheduled program is usually to catalyze the discovery of innovative biomarkers that assist in early diagnosis, detection and disease monitoring of Lewy body dementias . The ADDF/LBDA plan awarded $125,000 to one educational scientist on the cutting edge of analysis for LBD. Related StoriesEstrogen-like drug might not be beneficial to women with Alzheimer's dementiaStudy finds great prevalence of dehydration in the elderly living in UK caution homesLewy Body Composite Risk Rating detects LBD and Parkinson's disease dementia in 3 minutes There is fantastic potential for results out of this task to possess applications to both Lewy body illnesses, which include Parkinson’s disease and Lewy body dementias, and Alzheimer’s disease, stated Howard Fillit, MD, the ADDF Executive Director.‘These results indicate that binge drinking during pregnancy continues to be a problem,’ wrote the experts, led by the CDC’s Claire M. Marchetta. The authors acknowledge study limitations, such as the data being subject and self-reported to biases, which can result in understimates. The survey was only given to people who have landline phones also, which may have skewed rates. The CDC says drinking while pregnant can lead to fetal alcohol spectrum disorders , which include fetal alcohol syndrome, alcohol-related neurodevelopmental disorder, and alcohol-related birth defects. Fetal alcoholic beverages syndrome is definitely the most severe end of the FASD-spectrum, and could lead to problems with learning, memory, vision or hearing.